Summary
Merck & Co., Inc. (MRK) reported a significant increase in sales to $46.0 billion for the fiscal year ended December 31, 2010. This growth was primarily driven by the full-year inclusion of results from the Schering-Plough merger completed in November 2009, which integrated legacy Schering-Plough products like Remicade and Nasonex, as well as Zetia and Vytorin. The company experienced challenges including patent expirations for key products such as Cozaar/Hyzaar, leading to sales declines in those areas. Additionally, Merck incurred substantial restructuring costs totaling $1.8 billion related to the integration of Schering-Plough, aiming for significant future cost savings. The company also faced increased expenses due to U.S. healthcare reform legislation and global austerity measures impacting pricing. Merck's pipeline shows progress with new approvals like Dulera and updated indications for Gardasil. However, the company also recorded a significant impairment charge of $1.7 billion related to the vorapaxar development program. Investors should note the ongoing arbitration with Centocor regarding Remicade and Simponi rights, which could materially affect future results.
Financial Highlights
53 data points| Revenue | $45.99B |
| Cost of Revenue | $18.40B |
| Gross Profit | $27.59B |
| R&D Expenses | $11.11B |
| SG&A Expenses | $13.13B |
| Interest Expense | $715.00M |
| Net Income | $861.00M |
| EPS (Basic) | $0.28 |
| EPS (Diluted) | $0.28 |
| Shares Outstanding (Basic) | 3K |
| Shares Outstanding (Diluted) | 3K |
Key Highlights
- 1Total sales reached $46.0 billion, a substantial increase driven by the full-year impact of the Schering-Plough merger.
- 2Key products like Singulair, Januvia, and Isentress showed growth, while Cozaar/Hyzaar sales declined due to patent expirations.
- 3Merck incurred $1.8 billion in restructuring costs related to the Schering-Plough integration, with expected annual savings of $2.7-$3.1 billion by 2012.
- 4The company recorded a $1.7 billion impairment charge for the vorapaxar clinical development program.
- 5U.S. healthcare reform legislation led to increased Medicaid rebates and other impacts, reducing revenue by approximately $170 million.
- 6The company is awaiting a decision in an arbitration proceeding with Centocor concerning marketing rights for Remicade and Simponi, with an unfavorable outcome potentially having a material adverse effect.
- 7Merck advanced its R&D pipeline with new drug approvals and filed applications, but also faced challenges like the vorapaxar development setback.